The expression profiles obtained allow breast cancer to be divided into four main groups, namely luminal A (50–60% of cases), luminal B (10% of cases), human epidermal growth factor receptor 2 (HER2)-positive (20% of cases) and basal-like triple-negative tumors, which represent about 10% of breast cancers. Here, ERBB2 is linked to breast carcinoma.